GenScript Biotech Corporation (GenScript; HKEX: 01548) announced that its U.S.-listed associate, Legend Biotech Corporation (Legend), has delivered initial clinical proof-of-concept for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy, in relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).

Legend’s Phase 1 data, released on 14 June 2026 and presented at the European Hematology Association 2026 Congress (Abstract #LB5006), show:

• Efficacy: A single infusion at the higher dose level (DL2) produced a 100% objective response rate (6/6 patients) and an 83.33% complete response rate (5/6 patients). All responses were ongoing at the data cutoff.

• Pharmacodynamics: LB2501 achieved dose-dependent in vivo CAR-T expansion without the need for lymphodepletion.

• Safety: No dose-limiting toxicities, serious adverse events, immune effector cell-associated neurotoxicity syndrome, or deaths were reported.

The announcement underscores LB2501’s potential as a first-in-class, in vivo, dual-targeting CAR-T approach for R/R B-NHL, while maintaining a favorable safety profile in the early-stage study.

GenScript cautions shareholders and prospective investors to remain mindful of investment risks when dealing in its securities. Further details are available in Legend’s press release on its investor relations website.